HIV Vaccines May Help Tamp Down Virus

A fraction of HIV patients in a small, uncontrolled study were able to stop antiretroviral therapy after receiving the immune boosters.

Feb 24, 2017
Kerry Grens

FLICKR, NIAIDSeveral HIV-positive volunteers have been off antiretroviral therapy for weeks—and in most cases, months—after receiving two experimental vaccines. Researchers reported the results of the 13-person trial, which did not include a control arm, at the Conference on Retroviruses and Opportunistic Infections in Seattle last week.

“The results are encouraging, but it is difficult to gauge what the effect of the procedure actually was because of the uncontrolled nature of the study and the fact that the people who remain off [ARVs] are, nevertheless, viremic,” Daniel Douek, an immunologist at the National Institute of Allergy and Infectious Diseases, told ScienceInsider.

All of the study participants had been on antiretroviral therapy before receiving two vaccines. Both immunizations were designed to direct cytotoxic T lymphocytes to attack conserved HIV proteins. Later, patients received a booster vaccine, along with a drug that activates latent HIV, before going off their HIV antiretroviral medications entirely.

According to news reports, eight volunteers in the study had to resume antiretroviral therapy, but the other five remain off the treatment—now, six weeks to seven months after cessation—with viral loads that appear to be under control.

“This is the first reported immune intervention demonstrating a manipulation of the [cytotoxic T lymphocyte] immunodominance pattern and a durable viremic control of HIV-1 infection in a large proportion of participants,” Beatriz Mothe of IrsiCaixa AIDS Research Institute in Barcelona, Spain, and her colleagues wrote in their presentation abstract.

“Should the current trends persist, it is hard to argue that the vaccine strategy did not do something,” Steven Deeks, an HIV researcher at the University of California, San Francisco, told Tech Times. “But controlled studies are needed.”

November 2018

Intelligent Science

Wrapping our heads around human smarts


Sponsored Product Updates

Complete Pathology Solutions: Make Every Minute Count

Complete Pathology Solutions: Make Every Minute Count

From sample collection and handling, to fixation and processing, tissue staining, and covering all your IHC and water purification needs—you can have confidence in the quality of your results with MilliporeSigma's one-stop pathology solution.

Preparing Cell Or Tissue Lysates For ELISA Kits

Preparing Cell Or Tissue Lysates For ELISA Kits

RayBiotech manufactures over 2,000 high fully validated, GMP-compliant ELISA kits. In this blog post we explain how to prepare cell or tissue lysates for ELISA Kits.

Norgen Biotek Achieves Illumina Propel Certification as a Service Provider for Next Generation Sequencing

Norgen Biotek Achieves Illumina Propel Certification as a Service Provider for Next Generation Sequencing

Norgen Biotek Corp., an innovative privately held Canadian biotechnology company focusing primarily on nucleic acid and protein stabilization and purification, as well as providing high quality services to the scientific community, today announced that it has become Propel-Certified through Illumina as a Next Generation Sequencing (NGS) service provider.

Slice® Safety Cutters for Lab Work

Slice® Safety Cutters for Lab Work

Slice cutting tools—which feature our patent-pending safety blades—meet many lab-specific requirements. Our scalpels and craft knives are well suited for delicate work, and our utility knives are good for general use.